Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 107, Issue 1, Pages 37-42
Publisher
Springer Nature
Online
2012-05-30
DOI
10.1038/bjc.2012.233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
- (2012) Elizabeth S. Nakasone et al. CANCER CELL
- Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
- (2012) A. Calcinotto et al. JOURNAL OF IMMUNOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy
- (2011) E. Dondossola et al. CANCER RESEARCH
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
- (2010) A. Poveda et al. ANNALS OF ONCOLOGY
- Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
- (2010) A Santoro et al. BRITISH JOURNAL OF CANCER
- Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
- (2010) H. W.M. van Laarhoven et al. CLINICAL CANCER RESEARCH
- Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study
- (2010) Peter G. Rose et al. GYNECOLOGIC ONCOLOGY
- Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma
- (2010) Vanesa Gregorc et al. JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
- (2009) V Gregorc et al. BRITISH JOURNAL OF CANCER
- Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours
- (2009) Vanesa Gregorc et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic drugs in ovarian cancer
- (2008) G C Kumaran et al. BRITISH JOURNAL OF CANCER
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation